| USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17.59M | 11.88M | 32.20M | 40.50M | 30.95M |
| YoY Growth | +48.1% | -63.1% | -20.5% | +30.9% | — |
| Gross Profit | (3.56M) | (2.40M) | (8.70M) | 1.85M | 1.49M |
| Gross Margin | -20.2% | -20.2% | -27.0% | 4.6% | 4.8% |
| R&D | 688,000 | 1.13M | 2.64M | 3.58M | 3.91M |
| SG&A | 7.59M | 10.29M | 31.83M | 32.23M | 25.91M |
| EBIT | (11.42M) | (13.37M) | (45.27M) | (36.48M) | (32.54M) |
| EBIT Margin | -64.9% | -112.6% | -140.6% | -90.1% | -105.1% |
| D&A | 1.16M | 1.26M | 4.86M | 3.59M | 1.54M |
| EBITDA | (10.26M) | (12.11M) | (40.41M) | (32.89M) | (31.00M) |
| EBITDA Margin | -58.3% | -102.0% | -125.5% | -81.2% | -100.2% |
| Net Income | (13.12M) | (15.16M) | (140.78M) | (59.80M) | (32.61M) |
| Net Margin | -74.6% | -127.7% | -437.1% | -147.7% | -105.4% |
| EPS (diluted) | $-52.87 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares (dil., M) | 0 | 0 | 0 | 0 | 0 |
Company Brief
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
| Gross Margin | -20.2% |
| EBITDA Margin | -58.3% |
| EBIT Margin | -64.9% |
| Net Margin | -28.7% |
| FCF Margin | -44.3% |
| ROE | -43.8% |
| ROIC | -56.6% |
| ROA | -18.7% |
| ROCE | -57.8% |
| Asset Turnover | 0.65× |
| ROIC | -56.6% |
| ROE | -43.8% |
| ROA | -18.7% |
| ROCE | -57.8% |
| Asset Turnover | 0.65× |
| FCF Margin | -44.3% |
| Net Margin | -28.7% |
| Insider buys (12m) | — |
| Insider sells (12m) | — |
| Float | 80.0% |
| Shares Out. | 166,912 |
| Mean Target | $82.50 |
| Median Target | $82.50 |
| High Target | $90 |
| Low Target | $75 |
| vs. Mean | +3633.0% |
| Buy / Hold / Sell | — |
| Cash & ST Invest. | $7.1M |
| Total Debt | $4.2M |
| Net Cash / (Debt) | $2.9M |
| Total Assets | $27.0M |
| Total Equity | $15.8M |
| Goodwill & Intang. | $6.2M |
| Tangible Book/sh | $51.80 |
| Current Ratio | 2.42× |
| Quick Ratio | 1.83× |
| D/E Ratio | 0.27× |
| Debt / Assets | 15.6% |
| Net Debt / EBITDA | 0.29× |
| Interest Coverage | -7.85× |
| Beta (5yr) | 1.03 |
| Revenue 1yr | +48.1% |
| Revenue 3yr | -24.3% |
| Revenue 5yr | -13.2% |
| EPS 1yr | — |
| EPS 3yr | — |
| EPS 5yr | — |
| FCF 5yr | — |
| Dividend 5yr | — |
No dividend paid.
| Capex | $61K |
| Capex / Revenue | 0.3% |
| SBC | $421K |
| Dividends Paid | $0 |
| Buybacks | $0 |
| Gross Margin | -20.2% |
| EBITDA Margin | -58.3% |
| EBIT Margin | -64.9% |
| Net Margin | -28.7% |
| FCF Margin | -44.3% |
| ROE | -43.8% |
| ROIC | -56.6% |
| ROA | -18.7% |
| ROCE | -57.8% |
| Asset Turnover | 0.65× |
| ROIC | -56.6% |
| ROE | -43.8% |
| ROA | -18.7% |
| ROCE | -57.8% |
| Asset Turnover | 0.65× |
| FCF Margin | -44.3% |
| Net Margin | -28.7% |
| Insider buys (12m) | — |
| Insider sells (12m) | — |
| Float | 80.0% |
| Shares Out. | 166,912 |
| Mean Target | $82.50 |
| Median Target | $82.50 |
| High Target | $90 |
| Low Target | $75 |
| vs. Mean | +3633.0% |
| Buy / Hold / Sell | — |
| USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17.59M | 11.88M | 32.20M | 40.50M | 30.95M |
| YoY Growth | +48.1% | -63.1% | -20.5% | +30.9% | — |
| Gross Profit | (3.56M) | (2.40M) | (8.70M) | 1.85M | 1.49M |
| Gross Margin | -20.2% | -20.2% | -27.0% | 4.6% | 4.8% |
| R&D | 688,000 | 1.13M | 2.64M | 3.58M | 3.91M |
| SG&A | 7.59M | 10.29M | 31.83M | 32.23M | 25.91M |
| EBIT | (11.42M) | (13.37M) | (45.27M) | (36.48M) | (32.54M) |
| EBIT Margin | -64.9% | -112.6% | -140.6% | -90.1% | -105.1% |
| D&A | 1.16M | 1.26M | 4.86M | 3.59M | 1.54M |
| EBITDA | (10.26M) | (12.11M) | (40.41M) | (32.89M) | (31.00M) |
| EBITDA Margin | -58.3% | -102.0% | -125.5% | -81.2% | -100.2% |
| Net Income | (13.12M) | (15.16M) | (140.78M) | (59.80M) | (32.61M) |
| Net Margin | -74.6% | -127.7% | -437.1% | -147.7% | -105.4% |
| EPS (diluted) | $-52.87 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares (dil., M) | 0 | 0 | 0 | 0 | 0 |
Company Brief
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
| Cash & ST Invest. | $7.1M |
| Total Debt | $4.2M |
| Net Cash / (Debt) | $2.9M |
| Total Assets | $27.0M |
| Total Equity | $15.8M |
| Goodwill & Intang. | $6.2M |
| Tangible Book/sh | $51.80 |
| Current Ratio | 2.42× |
| Quick Ratio | 1.83× |
| D/E Ratio | 0.27× |
| Debt / Assets | 15.6% |
| Net Debt / EBITDA | 0.29× |
| Interest Coverage | -7.85× |
| Beta (5yr) | 1.03 |
| Revenue 1yr | +48.1% |
| Revenue 3yr | -24.3% |
| Revenue 5yr | -13.2% |
| EPS 1yr | — |
| EPS 3yr | — |
| EPS 5yr | — |
| FCF 5yr | — |
| Dividend 5yr | — |
No dividend paid.
| Capex | $61K |
| Capex / Revenue | 0.3% |
| SBC | $421K |
| Dividends Paid | $0 |
| Buybacks | $0 |